Gemcitabine is considered to be a well-tolerated and safe infusion of granisetron, dexamethasone sodium phosphate and furosemide on day 15 before administration of cisplatin. The cytostatic drug because of the relative lack of side eOE ects. Cutaneous reactions due to gemcitabine treatment, including second cycle of treatment was postponed, with the dosage of gemcitabine reduced to 888 mg/m2 due to persistent thromalopecia and maculopapular eruption, are well known. We report one patient with squamous cell carcinoma of the lung who bocytopenia. Three days after the ® rst injection of gemcitabine of the second cycle, diOE use erythema, swelling, tenderness and developed a gemcitabine-induced cutaneous reaction mimicking acute lipodermatosclerosis. This case has never been reported in local heat were noted on both the patient's lower legs. Oral amoxicillin was administered for 10 days under the impression the literature before. Key words: Gemzar â ; lipomembranous change; lipomembranous fat necrosis; skin toxicity.
Gemcitabine (di¯uorodeoxycytidine, 2¾ ,2¾ -di¯uorodeoxycytid-ine; dFdC ) is a deoxycytidine analogue with structural and metabolic similarities to cytarabine (ara-C) (1) . It mimics the structure of the natural nucleoside and, following phosphorylation, is incorporated into DNA (2) . Several previous reports have shown that gemcitabine alone or in combination with cisplatin is active against non-small-cell lung cancer with little cutaneous toxicities (2, 3) . Gemcitabine is considered to be a well-tolerated and safe cytostatic drug because of the relative lack of side eOE ects, which include nausea, emesis, myelosuppression, general weakness, peripheral oedema and¯u-like symptoms (4) . Its cutaneous reactions, such as alopecia and a maculopapular rash, are well documented (4± 7). A phase II randomized study of gemcitabine treatment in inoperable nonsmall-cell lung cancer conducted in Taiwan revealed the occurrence of World Health Organization ( WHO) grade I and grade II skin toxicities in 33.3% of the total 27 patients (5). Reports from the United States, the United Kingdom and Denmark also revealed that the incidence of cutaneous toxicity due to gemcitabine treatment was about 25.7± 39% (6, 7). The skin toxicity was a transient rash which tended to be macular and did not occur with every course of therapy (7). Here, we report a case of gemcitabine-induced cutaneous reaction mimicking acute lipodermatosclerosis (LDS). To the best of our knowledge, it is the ® rst report of acute LDS-like reaction due to an antineoplastic agent.
CASE REPORT
A 70-year-old male was diagnosed as having stage IIIb squamous cell carcinoma of the lung in 1999. His body surface area was 1.8 m2. Chemotherapy had been administered with intravenous infusion of gemcitabine 1000 mg/m2 for 30 min on days 1, 8 and 15, as well as intravenous infusion of cisplatin 120 mg skin injury over this area nor extravasation during infusion of when the patient received further injections of gemcitabine. After completing all 6 courses of gemcitabine and cisplatin gemcitabine and cisplatin. A skin biopsy specimen taken from the erythematous, indurated plaque showed pictures of stasis treatment, there was brownish pigmentation and induration of both lower legs with no recurrence of acute LDS during dermatitis with capillary proliferation in the upper dermis, as well as hyalinized sclerosis, septal ® brosis and remarkable the following 5-month follow-up period. Poor wound healing of the biopsy sites was also noted. The patient expired, due to lipomembranous change in the subcutis (Fig. 2) Although lipomembranous fat necrosis is a non-speci® c form of ischaemic fat degeneration that could be induced by conditions such as erythema nodosum, morphea profunda, lupus panniculitis, necrobiosis lipoidica, polyarteritis nodosa, necrotizing vasculitis and erysipelas, it is most prominent and most commonly found in venous stasis-associated chronic sclerotic plaques that are typically seen in middle-aged obese women (14) . The patient had no clinical evidence of venous insu ciency, but the histopathological studies revealed proliferation of dermal capillaries, which was a typical stasis change. In addition, the positive 3 P test result, increased levels of ® brinogen, FDP and d-dimer, as well as a low functional level of protein C, all pointed to an underlying venous thrombotic state.
Since gemcitabine is closely related to cytarabine, a drug that is well known to induce acral erythema (15± 18), the skin reactions in this patient could be acral erythema (erythrodysaesthesia syndrome) localized to the area of LDS. In addition, ® xed drug eruption could be another possible diagnosis. Nevertheless, both can easily be excluded in lacking the characteristic histologic features, such as vacuolar degeneration of the basal layer and scattered necrotic and dyskeratotic keratinocytes (15). The patient could have acute LDS per se 
